KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Gross Margin (2020 - 2025)

Vir Biotechnology (VIR) has disclosed Gross Margin for 6 consecutive years, with 99.09% as the latest value for Q2 2025.

  • Quarterly Gross Margin rose 78.0% to 99.09% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 96.08% through Jun 2025, down 264.0% year-over-year, with the annual reading at 99.96% for FY2025, 110.0% up from the prior year.
  • Gross Margin hit 99.09% in Q2 2025 for Vir Biotechnology, down from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2021 to a low of 31.28% in Q2 2022.
  • Historically, Gross Margin has averaged 92.81% across 5 years, with a median of 97.44% in 2024.
  • Biggest five-year swings in Gross Margin: crashed -6804bps in 2022 and later soared 6814bps in 2023.
  • Year by year, Gross Margin stood at 93.0% in 2021, then decreased by -6bps to 87.86% in 2022, then rose by 8bps to 95.25% in 2023, then fell by -1bps to 94.47% in 2024, then rose by 5bps to 99.09% in 2025.
  • Business Quant data shows Gross Margin for VIR at 99.09% in Q2 2025, 100.0% in Q1 2025, and 94.47% in Q4 2024.